Umberto Ricardi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9291413/publications.pdf

Version: 2024-02-01

288 papers 10,197 citations

47006 47 h-index 87 g-index

289 all docs

289 docs citations

times ranked

289

11414 citing authors

#	Article	IF	CITATIONS
1	An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer. Radiotherapy and Oncology, 2022, 167, 187-194.	0.6	21
2	The Impact of the COVID-19 Pandemic on Head and Neck Cancer Diagnosis in the Piedmont Region, Italy: Interrupted Time-Series Analysis. Frontiers in Public Health, 2022, 10, 809283.	2.7	13
3	Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC. Cancers, 2022, 14, 1465.	3.7	O
4	Development of a prognostic model of overall survival in oropharyngeal cancer from real-world data: PRO.M.E.THE.O Acta Otorhinolaryngologica Italica, 2022, , 1-10.	1.5	0
5	Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 114, 892-901.	0.8	6
6	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nature Medicine, 2022, 28, 752-765.	30.7	30
7	Sinonasal Side Effects of Chemotherapy and/or Radiation Therapy for Head and Neck Cancer: A Literature Review. Cancers, 2022, 14, 2324.	3.7	12
8	An integrated approach to cardioprotection in lymphomas. Lancet Haematology, the, 2022, 9, e445-e454.	4.6	5
9	Predictors of Bone Metastases at 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence. Diagnostics, 2022, 12, 1309.	2.6	5
10	Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice. Radiologia Medica, 2021, 126, 142-146.	7.7	27
11	Adoption of Expansion Margins to Reduce the Dose Received by the Coronary Arteries and the Risk of Cardiovascular Events in Lymphoma Patients. Practical Radiation Oncology, 2021, 11, 66-73.	2.1	4
12	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	2.2	0
13	Role of Radiotherapy in Post-transplant Lymphoproliferative Disorders: Three Case Reports and Review of the Literature. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e309-e316.	0.4	3
14	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. Radiotherapy and Oncology, 2021, 154, 269-273.	0.6	11
15	COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2. Radiotherapy and Oncology, 2021, 155, 120-122.	0.6	5
16	Cardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy – Old Foes Still Threatening Cancer Survivors?. Frontiers of Hormone Research, 2021, 54, 115-129.	1.0	1
17	Safety of lung stereotactic ablative radiotherapy for the functioning of cardiac implantable electronic devices. Radiotherapy and Oncology, 2021, 156, 193-198.	0.6	4
18	Decreasing treatment burden in HPV-related OPSCC: A systematic review of clinical trials. Critical Reviews in Oncology/Hematology, 2021, 160, 103243.	4.4	10

#	Article	IF	Citations
19	How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). Cancers, 2021, 13, 2702.	3.7	4
20	Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiologia Medica, 2021, 126, 1117-1128.	7.7	18
21	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 296.e21-296.e29.	1.6	24
22	Concurrent Chemoradiation in Anal Cancer Patients Delivered with Bone Marrow-Sparing IMRT: Final Results of a Prospective Phase II Trial. Journal of Personalized Medicine, 2021, 11, 427.	2.5	6
23	An external validation of the Candiolo nomogram in a cohort of prostate cancer patients treated by externalâ€beam radiotherapy. Radiation Oncology, 2021, 16, 85.	2.7	2
24	Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. Neuro-Oncology, 2021, 23, 1750-1764.	1.2	28
25	European radiation oncology after one year of COVID-19 pandemic. Clinical and Translational Radiation Oncology, 2021, 28, 141-143.	1.7	11
26	Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients. Hematology Reports, 2021, 13, 9080.	0.8	7
27	Efficacy of low-dose radiotherapy (2 Gy $\tilde{A}-$ 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas. British Journal of Radiology, 2021, 94, 20210012.	2.2	7
28	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1064-1081.	0.8	26
29	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. Annals of Hematology, 2021, 100, 2547-2556.	1.8	1
30	A bond between rheumatic diseases and cancer in the elderly: The interleukinâ€6 pathway. International Journal of Rheumatic Diseases, 2021, 24, 1317-1320.	1.9	14
31	An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases. Radiotherapy and Oncology, 2021, 164, 98-103.	0.6	14
32	Late metastatic presentation is associated with improved survival and delayed wideâ€spread progression after ablative stereotactic body radiotherapy for oligometastasis. Cancer Medicine, 2021, 10, 6189-6198.	2.8	6
33	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. Clinical Lung Cancer, 2021, 22, 579-586.	2.6	9
34	Harnessing benefit of highly conformal RT techniques for lymphoma patients. British Journal of Radiology, 2021, 94, 20210469.	2.2	4
35	Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model. Radiologia Medica, 2021, 126, 1619-1656.	7.7	33
36	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Advances, 2021, 5, 4504-4514.	5.2	14

#	Article	IF	CITATIONS
37	Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease. Cancer Medicine, 2021, 10, 8091-8099.	2.8	4
38	The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment. Critical Reviews in Oncology/Hematology, 2021, 168, 103497.	4.4	17
39	Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions. Frontiers in Oncology, 2021, 11, 772789.	2.8	25
40	The role of motion management and position verification in lymphoma radiotherapy. British Journal of Radiology, 2021, 94, 20210618.	2.2	6
41	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncology, The, 2020, 21, e18-e28.	10.7	588
42	Separation surgery for metastatic epidural spinal cord compression: A qualitative review. Journal of Bone Oncology, 2020, 25, 100320.	2.4	43
43	National societies' needs as assessed by the ESTRO National Societies Committee survey: A European perspective. Radiotherapy and Oncology, 2020, 151, 176-181.	0.6	3
44	The importance of IL-6 blockade beyond the COVID-19 pandemic: Consideration for cancer care. Radiotherapy and Oncology, 2020, 151, 24-25.	0.6	2
45	Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial. Cancers, 2020, 12, 3306.	3.7	18
46	Radiation-Induced Lymphopenia Beyond the COVID-19 Pandemic. Frontiers in Oncology, 2020, 10, 617302.	2.8	5
47	<p>Ocular Complications After Radiation Therapy: An Observational Study</p> . Clinical Ophthalmology, 2020, Volume 14, 3153-3166.	1.8	19
48	A study to investigate the influence of cardiac motion on the robustness of pencil beam scanning proton plans in oesophageal cancer. Physics and Imaging in Radiation Oncology, 2020, 16, 50-53.	2.9	3
49	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. Cancers, 2020, 12, 3131.	3.7	13
50	Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis. JAMA Network Open, 2020, 3, e2026312.	5.9	51
51	Running a Radiation Oncology Department at the Time of Coronavirus: An Italian Experience. Advances in Radiation Oncology, 2020, 5, 3-6.	1.2	10
52	COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiotherapy and Oncology, 2020, 149, 89-93.	0.6	43
53	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. Blood Advances, 2020, 4, 2064-2072.	5 . 2	6
54	Effect of COVID-19 pandemic on practice in European radiation oncology centers. Radiotherapy and Oncology, 2020, 150, 40-42.	0.6	53

#	Article	IF	Citations
55	ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood, 2020, 135, 1829-1832.	1.4	78
56	Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459). Radiotherapy and Oncology, 2020, 146, 136-142.	0.6	28
57	Running a Radiation Oncology Department at the Time of Coronavirus: An Italian Experience. Advances in Radiation Oncology, 2020, 5, 527-530.	1.2	65
58	Radiation therapy for oligometastatic oropharyngeal cancer. BJR case Reports, 2020, 6, 20190021.	0.2	2
59	Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum. Radiation Oncology, 2020, 15, 62.	2.7	20
60	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.8	40
61	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood, 2020, 135, 2365-2374.	1.4	30
62	ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. Radiotherapy and Oncology, 2020, 152, 89-95.	0.6	23
63	What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?. Lung Cancer, 2020, 146, 263-275.	2.0	4
64	Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy. Acta Oncol \tilde{A}^3 gica, 2020, 59, 541-548.	1.8	17
65	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology Biology Physics, 2020, 107, 909-933.	0.8	67
66	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.6	168
67	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology, 2020, 148, 157-166.	0.6	352
68	Automatic genetic planning for volumetric modulated arc therapy: A large multi-centre validation for prostate cancer. Radiotherapy and Oncology, 2020, 148, 126-132.	0.6	12
69	"Miro―Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma Journal of Clinical Oncology, 2020, 38, e20073-e20073.	1.6	1
70	GCT-48. OUTCOME OF CNS MALIGNANT NON-GERMINOMATOUS GERM CELL TUMORS (GCT) WITH AFP & amp;gt; 1000 ng/ml AT DIAGNOSIS TREATED ACCORDING TO SIOP CNS GCT 96. Neuro-Oncology, 2020, 22, iii337-iii338.	1.2	0
71	The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. Minerva Urology and Nephrology, 2020, , .	2.5	1
72	A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). Radiotherapy and Oncology, 2019, 131, 208-214.	0.6	9

#	Article	IF	CITATIONS
73	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). Tumori, 2019, 105, 3-14.	1.1	9
74	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. PLoS ONE, 2019, 14, e0224027.	2.5	5
75	<p>Proton Therapy For Lymphomas: Current State Of The Art</p> . OncoTargets and Therapy, 2019, Volume 12, 8033-8046.	2.0	17
76	<p>Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) Tj ETQq0 0 C</p>) rgBIJ9/Ov	erlo za 10 Tf 5
77	Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients. Radiotherapy and Oncology, 2019, 138, 52-58.	0.6	32
78	The role of radiotherapy in epithelial ovarian cancer: a literature overview. Medical Oncology, 2019, 36, 64.	2.5	20
79	Applying radiation protection and safety in radiotherapy. Radiologia Medica, 2019, 124, 777-782.	7.7	11
80	Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey. Journal of Contemporary Brachytherapy, 2019, 11, 48-53.	0.9	26
81	Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. Journal of Neuro-Oncology, 2019, 143, 447-455.	2.9	6
82	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. International Journal of Radiation Oncology Biology Physics, 2019, 104, 522-529.	0.8	16
83	Radiation Oncology. Optimal Health for All, Together. ESTRO vision, 2030. Radiotherapy and Oncology, 2019, 136, 86-97.	0.6	24
84	Prospective assessment of taste impairment and nausea during radiotherapy for head and neck cancer. Medical Oncology, 2019, 36, 44.	2.5	19
85	Clinical evaluation of a transmission detector system and comparison with a homogeneous 3D phantom dosimeter. Physica Medica, 2019, 58, 159-164.	0.7	11
86	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 (Reviews in Oncology/Hematology, 2019, 134, 104-119.	0 0 rgBT /0 4.4	Overlock 10 T
87	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood, 2019, 133, 237-245.	1.4	85
88	Radiation-Induced Rhinitis: Cytological and Olfactory Changes. American Journal of Rhinology and Allergy, 2019, 33, 153-161.	2.0	16
89	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 Reviews in Oncology/Hematology, 2019, 134, 87-103.	. 0.784314 4.4	4 rgBT /Over 7
90	EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. Blood, 2019, 134, 124-124.	1.4	6

#	Article	IF	Citations
91	Do hypofraction and large breast size reciprocally fit in breast cancer radiotherapy?. Annals of Translational Medicine, 2019, 7, S146-S146.	1.7	2
92	Primary tumor size as a prognosticator in anal cancer patients. Annals of Translational Medicine, 2019, 7, 157-157.	1.7	2
93	Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. Journal of Neuropathology and Experimental Neurology, 2019, 78, 248-256.	1.7	10
94	Title is missing!. , 2019, 14, e0224027.		0
95	Title is missing!. , 2019, 14, e0224027.		0
96	Title is missing!. , 2019, 14, e0224027.		0
97	Title is missing!. , 2019, 14, e0224027.		0
98	Title is missing!. , 2019, 14, e0224027.		0
99	Title is missing!. , 2019, 14, e0224027.		0
100	De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients. Medical Oncology, 2018, 35, 62.	2.5	24
101	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1100-1118.	0.8	46
102	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood, 2018, 131, 1456-1463.	1.4	130
103	Plan optimization for mediastinal radiotherapy: Estimation of coronary arteries motion with ECG-gated cardiac imaging and creation of compensatory expansion margins. Radiotherapy and Oncology, 2018, 127, 481-486.	0.6	25
104	ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2018, 127, 1-5.	0.6	141
105	Imageâ€guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 217-223.	1.1	33
106	Stage I Nonsmall Cell Lung Cancer and Oligometastatic Disease. , 2018, , 342-354.e4.		0
107	Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Radiologia Medica, 2018, 123, 48-62.	7.7	20
108	Intensity Modulated Radiation Therapy and Second Cancer Risk in Adults. International Journal of Radiation Oncology Biology Physics, 2018, 100, 17-20.	0.8	29

#	Article	IF	Citations
109	Volumetric modulated arc therapy (VMAT) to deliver nodal irradiation in breast cancer patients. Medical Oncology, 2018, 35, 1.	2.5	24
110	Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 519-531.	2.8	106
111	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. Journal of Thoracic Disease, 2018, 10, S1461-S1467.	1.4	25
112	Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients. Medical Oncology, 2018, 35, 150.	2.5	7
113	Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study. Radiation Oncology, 2018, 13, 172.	2.7	19
114	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. PLoS ONE, 2018, 13, e0203570.	2.5	11
115	Variability of clinical target volume delineation for rectal cancer patients planned for neoadjuvant radiotherapy with the aid of the platform Anatom-e. Clinical and Translational Radiation Oncology, 2018, 11, 33-39.	1.7	20
116	Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation. Cancer Investigation, 2018, 36, 279-288.	1.3	8
117	Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiotherapy and Oncology, 2018, 128, 260-265.	0.6	123
118	Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 101, 794-808.	0.8	128
119	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treatment Reviews, 2018, 69, 215-223.	7.7	19
120	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. Radiation Oncology, 2018, 13, 83.	2.7	23
121	Automated Heuristic Optimization of Prostate VMAT Treatment Planning. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2018, 07, 414-425.	0.1	4
122	Simulation modeling for clinical trials evaluating radiotherapy omission in low-risk early breast cancer. Annals of Translational Medicine, 2018, 6, S43-S43.	1.7	0
123	Management of acute skin toxicity with Hypericum perforatum and neem oil during platinum-based concurrent chemo-radiation in head and neck cancer patients. Medical Oncology, 2017, 34, 30.	2.5	13
124	Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective. Expert Review of Anticancer Therapy, 2017, 17, 335-345.	2.4	19
125	Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. Expert Review of Anticancer Therapy, 2017, 17, 347-356.	2.4	18
126	A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. Future Oncology, 2017, 13, 1081-1089.	2.4	13

#	Article	IF	Citations
127	Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Medical Oncology, 2017, 34, 40.	2.5	6
128	Prospective assessment of oral mucositis and its impact on quality of life and patient-reported outcomes during radiotherapy for head and neck cancer. Medical Oncology, 2017, 34, 81.	2.5	37
129	What do radiation oncologists require for future advancements in lung SBRT?. Physica Medica, 2017, 44, 150-156.	0.7	7
130	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treatment Reviews, 2017, 53, 25-37.	7.7	169
131	Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. International Journal of Radiation Oncology Biology Physics, 2017, 99, 825-842.	0.8	66
132	Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup. ESMO Open, 2017, 2, e000141.	4.5	0
133	Ex vivo Î ³ H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. Radiotherapy and Oncology, 2017, 124, 386-394.	0.6	18
134	Outcome of patients with intracranial non-germinomatous germ cell tumorsâ€"lessons from the SIOP-CNS-GCT-96 trial. Neuro-Oncology, 2017, 19, 1661-1672.	1.2	150
135	No differences in radiological changes after 3D conformal <i>vs</i> VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer. British Journal of Radiology, 2017, 90, 20170143.	2.2	13
136	Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncology, The, 2017, 18, e379-e393.	10.7	15
137	Radiation therapy for older patients with brain tumors. Radiation Oncology, 2017, 12, 101.	2.7	32
138	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 42-49.	0.8	31
139	Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 14-22.	0.4	19
140	Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. European Urology Focus, 2017, 3, 321-324.	3.1	15
141	Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation. BMC Cancer, 2017, 17, 710.	2.6	20
142	Role of consolidative stereotactic ablative radiotherapy in patients with oligometastatic non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 2235-2237.	1.4	4
143	Treatment of metastatic melanoma: a multidisciplinary approach. Italian Journal of Dermatology and Venereology, 2017, 152, 241-261.	0.2	4
144	Radiotherapy treatment strategies for squamous cell carcinoma of the cervical oesophagus: moving toward better outcomes. Annals of Translational Medicine, 2017, 5, 426-426.	1.7	0

#	Article	IF	CITATIONS
145	LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016041.	1.3	12
146	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. Leukemia and Lymphoma, 2016, 57, 2677-2680.	1.3	2
147	Post-ABVD/pre-radiotherapy ¹⁸ F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. British Journal of Radiology, 2016, 89, 20150983.	2.2	12
148	A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up*. Acta Oncológica, 2016, 55, 633-637.	1.8	26
149	Paediatric radiation oncology in the care of childhood cancer: A position paper by the International Paediatric Radiation Oncology Society (PROS). Radiotherapy and Oncology, 2016, 119, 357-360.	0.6	14
150	Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3Âcm. Medical Oncology, 2016, 33, 104.	2.5	4
151	Hypofractionation with no boost after breast conservation in early-stage breast cancer patients. Medical Oncology, 2016, 33, 108.	2.5	11
152	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. Lung Cancer, 2016, 100, 30-37.	2.0	3
153	Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma. Radiologia Medica, 2016, 121, 873-881.	7.7	14
154	Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study. Acta Oncol \mathring{A}^3 gica, 2016, 55, 1450-1455.	1.8	6
155	Hypofractionated Whole-Breast Radiotherapy and Concomitant Boost after Breast Conservation in Elderly Patients. Tumori, 2016, 102, 196-202.	1.1	13
156	Risk Stratification System and Pattern of Relapse in Patients Treated with Adjuvant Radiotherapy after Radical Prostatectomy. Tumori, 2016, 102, 323-329.	1.1	1
157	Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1454-1459.	0.8	21
158	Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiotherapy and Oncology, 2016, 120, 1-12.	0.6	44
159	Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients. Medical Oncology, 2016, 33, 72.	2.5	27
160	Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. British Journal of Radiology, 2016, 89, 20150832.	2.2	38
161	MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer: Table 1 Neuro-Oncology, 2016, 18, 598-599.	1.2	15
162	Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. Journal of Radiation Research, 2016, 57, i58-i68.	1.6	30

#	Article	IF	CITATIONS
163	Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1546-1562.	6.4	37
164	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 783-791.	0.8	35
165	Prognostic Role of Pre–Radiation Therapy 18F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1239-1243.	0.8	20
166	ESTRO-ACROP guideline "target delineation of glioblastomas― Radiotherapy and Oncology, 2016, 118, 35-42.	0.6	286
167	Ablative Approaches for Pulmonary Metastases. Thoracic Surgery Clinics, 2016, 26, 19-34.	1.0	12
168	Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. British Journal of Radiology, 2016, 89, 20160832.	2.2	7
169	Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. Anticancer Research, 2016, 36, 1943-8.	1.1	15
170	Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. Anticancer Research, 2016, 36, 2027-32.	1.1	18
171	Efficacy and Safety of Stereotactic Ablative Radiotherapy in Patients with Previous Pneumonectomy. Tumori, 2015, 101, 148-153.	1.1	7
172	YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study. PLoS ONE, 2015, 10, e0123759.	2.5	14
173	Bilateral Breast Radiation Delivered with Static Angle Tomotherapy (TomoDirect): Clinical Feasibility and Dosimetric Results of a Single Patient. Tumori, 2015, 101, e4-e8.	1.1	9
174	Stereotactic Ablative Radiation Therapy as First Local Therapy for Lung Oligometastases From Colorectal Cancer: A Single-Institution Cohort Study. International Journal of Radiation Oncology Biology Physics, 2015, 91, 524-529.	0.8	64
175	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1077-1083.	0.8	28
176	Results of Neoadjuvant Short-Course Radiation Therapy Followed by Transanal Endoscopic Microsurgery for T1-T2 NO Extraperitoneal Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 299-306.	0.8	41
177	Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study. Lung Cancer, 2015, 89, 350-356.	2.0	37
178	Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). Lung Cancer, 2015, 88, 160-166.	2.0	12
179	Optimized Volumetric Modulated Arc Therapy Versus 3D-CRT for Early Stage Mediastinal Hodgkin Lymphoma Without Axillary Involvement: A Comparison of Second Cancers and Heart Disease Risk. International Journal of Radiation Oncology Biology Physics, 2015, 92, 161-168.	0.8	55
180	Late Sensorial Alterations in Different Radiotherapy Techniques for Nasopharyngeal Cancer. Chemical Senses, 2015, 40, 285-292.	2.0	19

#	Article	IF	CITATIONS
181	Once-Weekly Hypofractionated Whole-Breast Radiotherapy After Breast-Conserving Surgery in Older Patients: A Potential Alternative Treatment Schedule to Daily 3-Week Hypofractionation. Clinical Breast Cancer, 2015, 15, 270-276.	2.4	33
182	Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence. Breast Care, 2015, 10, 44-49.	1.4	34
183	In Reply to Adams and Kwee. International Journal of Radiation Oncology Biology Physics, 2015, 93, 725-726.	0.8	2
184	Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost Combined with Concurrent Chemotherapy for the Treatment of Anal Cancer Patients: 4-Year Results of a Consecutive Case Series. Cancer Investigation, 2015, 33, 259-266.	1.3	42
185	FDG-PET and radiotherapy in lymphoma. Clinical and Translational Imaging, 2015, 3, 321-330.	2.1	0
186	Stereotactic body radiotherapy for early stage lung cancer: History and updated role. Lung Cancer, 2015, 90, 388-396.	2.0	62
187	Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma. Practical Radiation Oncology, 2015, 5, 383-389.	2.1	13
188	Residual \hat{I}^3 H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. Radiotherapy and Oncology, 2015, 116, 480-485.	0.6	37
189	Three-Dimensional Ultrasound-Based Image-Guided Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer: Results of a Consecutive Case Series. Cancer Investigation, 2015, 33, 23-28.	1.3	12
190	Stereotactic radiotherapy for early stage non-small cell lung cancer. Radiation Oncology Journal, 2015, 33, 57.	1.5	41
191	Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function. Anticancer Research, 2015, 35, 4177-82.	1.1	4
192	Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes. Anticancer Research, 2015, 35, 6247-54.	1.1	11
193	THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN'S LYMPHOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014035.	1.3	3
194	Minimizing a Tricky Situation in Breast Irradiation with Helical Tomotherapy. Tumori, 2014, 100, e35-e40.	1.1	2
195	Palliative Radiotherapy for Painful Bone Metastases from Solid Tumors Delivered with Static Ports of Tomotherapy (TomoDirect): Feasibility and Clinical Results. Cancer Investigation, 2014, 32, 458-463.	1.3	4
196	Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma. Strahlentherapie Und Onkologie, 2014, 190, 864-871.	2.0	16
197	Outcomes of Single Fraction Stereotactic Ablative Radiotherapy for Lung Metastases. Technology in Cancer Research and Treatment, 2014, 13, 37-45.	1.9	49
198	Hypericum perforatum and neem oil for the management of acute skin toxicity in head and neck cancer patients undergoing radiation or chemo-radiation: a single-arm prospective observational study. Radiation Oncology, 2014, 9, 297.	2.7	33

#	Article	IF	CITATIONS
199	Early Stage Lung Cancer: Progress in the Last 40 Years. Journal of Thoracic Oncology, 2014, 9, 1434-1442.	1.1	17
200	Stereotactic Ablative Radiotherapy for Pulmonary Oligometastases and Oligometastatic Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1426-1433.	1.1	49
201	Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e1-30.e7.	1.6	6
202	Daily Sodium Butyrate Enema for the Prevention of Radiation Proctitis in Prostate Cancer Patients Undergoing Radical Radiation Therapy: Results of a Multicenter Randomized Placebo-Controlled Dose-Finding Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 518-524.	0.8	29
203	Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial. Journal of Cancer Research and Clinical Oncology, 2014, 140, 167-177.	2.5	42
204	Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case series. Medical Oncology, 2014, 31, 838.	2.5	21
205	An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 346-355.	2.6	377
206	Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study. Lung Cancer, 2014, 84, 248-253.	2.0	73
207	Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer?. Reports of Practical Oncology and Radiotherapy, 2014, 19, 275-279.	0.6	21
208	Modern Radiation Therapy for Nodal Non-Hodgkin Lymphomaâ€"Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2014, 89, 49-58.	0.8	259
209	Involved-Site Image-Guided Intensity Modulated Versus 3D Conformal Radiation Therapy in Early Stage Supradiaphragmatic Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 370-375.	0.8	46
210	Changes in Patterns of Practice for Prostate Cancer Radiotherapy in Italy 1995–2003. A Survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori, 2014, 100, 31-37.	1.1	7
211	Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. World Journal of Urology, 2013, 31, 411-415.	2.2	12
212	Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Medical Oncology, 2013, 30, 581.	2.5	11
213	Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer. Medical Oncology, 2013, 30, 518.	2.5	31
214	Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1141-1147.	2.5	3
215	Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs. Radiotherapy and Oncology, 2013, 109, 95-99.	0.6	55
216	Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 311-316.	0.8	35

#	Article	IF	CITATIONS
217	SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro-Oncology, 2013, 15, 788-796.	1.2	277
218	Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leukemia and Lymphoma, 2013, 54, 1183-1187.	1.3	41
219	Postoperative Radiotherapy for Patients With Completely Resected Pathologic N2 Non–Small-Cell Lung Cancer: A Retrospective Analysis. Clinical Lung Cancer, 2013, 14, 194-199.	2.6	18
220	Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Critical Reviews in Oncology/Hematology, 2013, 85, 112-120.	4.4	21
221	Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Practical Radiation Oncology, 2013, 3, 216-222.	2.1	19
222	Second Italian Consensus Conference on Malignant Pleural Mesothelioma: State of the art and recommendations. Cancer Treatment Reviews, 2013, 39, 328-339.	7.7	51
223	Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): a prospective case series. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1927-1936.	2.5	41
224	May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1955-1960.	2.5	9
225	Salvage External Beam Radiotherapy for Recurrent Prostate Adenocarcinoma after High-Intensity Focused Ultrasound as Primary Treatment. Urologia Internationalis, 2013, 90, 288-293.	1.3	12
226	Comparison of Gafchromic EBT2 and EBT3 for patient-specific quality assurance: Cranial stereotactic radiosurgery using volumetric modulated arc therapy with multiple noncoplanar arcs. Medical Physics, 2013, 40, 082105.	3.0	25
227	New concepts and insights into the role of radiation therapy in extracranial metastatic disease. Expert Review of Anticancer Therapy, 2013, 13, 1145-1155.	2.4	14
228	Management of †In-Field' Skin Toxicity in Head and Neck Cancer Patients Treated with Combined Cetuximab and Radiotherapy. Oncology, 2013, 85, 257-261.	1.9	11
229	¹²⁵ I Brachytherapy for Localized Prostate Cancer: A Single Institution Experience. Tumori, 2013, 99, 83-87.	1.1	11
230	Leptomeningeal Metastasis from Prostate Cancer. Tumori, 2013, 99, e6-e10.	1.1	11
231	Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus. Tumori, 2013, 99, e80-e83.	1.1	13
232	Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro-Oncology, 2012, 14, 798-807.	1,2	26
233	Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. Oncologist, 2012, 17, 1100-1107.	3.7	185
234	Radiation therapy in locally advanced non-small-cell lung cancer: an overview of dose/fractionation strategies to improve outcomes. Lung Cancer Management, 2012, 1, 227-235.	1.5	0

#	Article	lF	Citations
235	The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy. Supportive Care in Cancer, 2012, 20, 2141-2147.	2.2	7
236	Role of Positron Emission Tomography-Computed Tomography in the Management of Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 66-72.	0.8	83
237	Treatment of brain metastases: Review of phase III randomized controlled trials. Radiotherapy and Oncology, 2012, 102, 168-179.	0.6	117
238	Adjuvant radiotherapy for malignant pleural mesothelioma: Challenges and pitfalls. Radiotherapy and Oncology, 2012, 105, 271.	0.6	0
239	Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, 1600-1607.	2.0	25
240	Epidemiology of glial and non-glial brain tumours in Europe. European Journal of Cancer, 2012, 48, 1532-1542.	2.8	248
241	Rare thoracic cancers, including peritoneum mesothelioma. European Journal of Cancer, 2012, 48, 949-960.	2.8	61
242	Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: Review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treatment Reviews, 2012, 38, 1033-1049.	7.7	106
243	Stereotactic body radiation therapy for lung metastases. Lung Cancer, 2012, 75, 77-81.	2.0	133
244	Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients. Acta Oncológica, 2012, 51, 618-623.	1.8	76
245	Does TomoDirect 3DCRT represent a suitable option for post-operative whole breast irradiation? A hypothesis-generating pilot study. Radiation Oncology, 2012, 7, 211.	2.7	33
246	Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiation Oncology, 2012, 7, 186.	2.7	96
247	Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: A monocentric study. Tumori, 2012, 98, 451-457.	1.1	6
248	Head and neck region consolidation radiotherapy and prophylactic cranial irradiation with hippocampal avoidance delivered with helical tomotherapy after induction chemotherapy for non-sinonasal neuroendocrine carcinoma of the upper airways. Radiation Oncology, 2012, 7, 21.	2.7	13
249	Innovative technologies in thoracic radiation therapy for lung cancer. Translational Lung Cancer Research, 2012, 1, 263-8.	2.8	3
250	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. Journal of Clinical Oncology, 2011, 29, 2766-2772.	1.6	190
251	Emerging treatment options in the management of non-small cell lung cancer. Lung Cancer: Targets and Therapy, 2011, 2, 11.	2.7	3
252	TomoDirect: An efficient means to deliver radiation at static angles with tomotherapy. Tumori, 2011, 97, 498-502.	1.1	33

#	Article	IF	CITATIONS
253	Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease. Strahlentherapie Und Onkologie, 2011, 187, 357-366.	2.0	28
254	Radiotherapy in Pleural Malignant Mesothelioma: Why not! in Regard to Scorsetti et al. (Int J Radiat) Tj ETQq0 0 0 International Journal of Radiation Oncology Biology Physics, 2011, 79, 1279.	rgBT /Ove 0.8	rlock 10 Tf 0
255	TomoDirect: an efficient means to deliver radiation at static angles with tomotherapy. Tumori, 2011, 97, 498-502.	1.1	29
256	Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007. Neurosurgery, 2010, 67, 446-458.	1.1	73
257	Efficacy and Safety of Tadalafil 20mg on Demand vs. Tadalafil 5mg Once-a-Day in the Treatment of Post-Radiotherapy Erectile Dysfunction in Prostate Cancer Men: A Randomized Phase II Trial. Journal of Sexual Medicine, 2010, 7, 2851-2859.	0.6	28
258	Comparison of Positron Emission Tomography Scanning and Sentinel Node Biopsy in the Detection of Inguinal Node Metastases in Patients With Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 73-78.	0.8	67
259	Polyostotic Sclerosing Histiocytosis (Erdheim-Chester Disease) Treated with Combined Vertebroplasty and Radiation Therapy. Tumori, 2010, 96, 633-636.	1.1	5
260	Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. Modern Pathology, 2010, 23, 260-269.	5. 5	24
261	Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung Cancer, 2010, 68, 72-77.	2.0	268
262	Eyelid Localization in Mantle Cell Lymphoma: Long-Lasting Complete Remission after Surface Brachytherapy. Tumori, 2009, 95, 385-388.	1.1	6
263	Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncol \tilde{A}^3 gica, 2009, 48, 571-577.	1.8	60
264	Late Toxicity in Children Undergoing Hematopoietic Stem Cell Transplantation with TBI-containing Conditioning Regimens for Hematological Malignancies. Strahlentherapie Und Onkologie, 2009, 185, 17-20.	2.0	31
265	YKL-40 expression in anal carcinoma predicts shorter overall and disease-free survival. Histopathology, 2009, 55, 238-240.	2.9	8
266	Pediatric medulloblastoma: Toxicity of current treatment and potential role of protontherapy. Cancer Treatment Reviews, 2009, 35, 79-96.	7.7	123
267	Two-tier analysis of histone H2AX phosphorylation allows the identification of Ataxia Telangiectasia heterozygotes. Radiotherapy and Oncology, 2009, 92, 133-137.	0.6	17
268	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood, 2009, 113, 3375-3382.	1.4	92
269	A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 508-516.	1.5	73
270	Absolute and relative dose measurements with Gafchromicâ,,¢ EBT film for high energy electron beams with different doses per pulse. Medical Physics, 2008, 35, 5463-5470.	3.0	13

#	Article	IF	CITATIONS
271	Activity of Weekly Paclitaxel in Advanced Hormone-Refractory Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 234-238.	1.3	6
272	Accessibility as a major determinant of radiotherapy underutilization: A population based study. Health Policy, 2007, 80, 483-491.	3.0	41
273	Stereotactic Body Radiation Therapy for Early Non-Small Cell Lung Cancer: Experience at the University of Turin. Journal of Thoracic Oncology, 2007, 2, S47.	1.1	9
274	Treatment options in skeletal localizations of hairy cell leukemia: A systematic review on the role of radiation therapy. American Journal of Hematology, 2007, 82, 1017-1021.	4.1	11
275	Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiation Oncology, 2007, 2, 15.	2.7	23
276	Scleromyxedema: treatment of widespread cutaneous involvement by total skin electron-beam therapy. International Journal of Dermatology, 2007, 46, 864-867.	1.0	10
277	Clinical use of EBT model Gafchromicâ,,¢ film in radiotherapy. Medical Physics, 2006, 33, 4314-4319.	3.0	153
278	A Case of Bone Involvement in Hairy Cell Leukemia Successfully Treated with Radiation Therapy. Tumori, 2006, 92, 366-369.	1.1	2
279	Is Clinical Radiosensitivity a Complex Genetically Controlled Event?. Tumori, 2006, 92, 87-91.	1.1	24
280	Peripheral blood complete remission after splenic irradiation in Mantle-Cell Lymphoma with 11q22-23 deletion and ATM inactivation. Radiation Oncology, 2006, 1, 35.	2.7	10
281	Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. International Journal of Radiation Oncology Biology Physics, 2006, 65, 788-799.	0.8	23
282	Adjuvant malignant mesothelioma radiotherapy: How many difficulties! In regard to: Allen et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma (Int J Radiat) Tj ETQq0 0 0 pleurectomy/decortication for malignant pleural mesothelioma (Int J Radiat Oncol Biol Phys) Tj ETQq0 0 0 rgBT/0	0.8	0
283	Is clinical radiosensitivity a complex genetically controlled event?. Tumori, 2006, 92, 87-91.	1.1	11
284	Treatment With Oral Etoposide for Childhood Recurrent Ependymomas. Journal of Pediatric Hematology/Oncology, 2005, 27, 486-490.	0.6	33
285	Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1336-1345.	0.8	93
286	Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1287-1294.	0.8	65
287	Survival trends of childhood cancer diagnosed during 1970-1994 in Piedmont, Italy: A report from the Childhood Cancer Registry. Medical and Pediatric Oncology, 2001, 36, 481-488.	1.0	13
288	Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 1996, 38, 561-565.	2.3	3